BIOMAT Database Logo BIOMAT Database Logo

Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. 1999

K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Department of Pathology, Sapporo Medical University School of Medicine, Japan.

Peptides of human melanomas recognized by CD8+ CTLs have been identified, but the nature of those of nonmelanoma tumors remains to be elucidated. Previously, we established a gastric signet ring cell carcinoma HST-2 and HLA-A31 (A*31012)-restricted autologous CTL clone, TcHST-2. In the present study, we determined the natural antigenic peptides of HST-2 cells. The purified preparation of acid-extracted Ags was submitted to the peptide sequencer, and one peptide, designated F4.2 (Tyr-Ser-Trp-Met-Asp-Ile-Ser-Cys-Trp-Ile), appeared to be immunogenic. To confirm the antigenicity of F4.2 further, we constructed an expression minigene vector (pF4.2ss) coding adenovirus E3, a 19-kDa protein signal sequence plus F4.2. An introduction of pF4.2ss minigene to HST-2 and HLA-A31(+) allogeneic tumor cells clearly enhanced and induced the TcHST-2 reactivity, respectively. Furthermore, when synthetic peptides of F4.2 C-terminal-deleted peptides were pulsed to HST-2 cells, F4.2-9 (nonamers), but not F4.2-8 or F4.2-7 (octamer or heptamer, respectively), enhanced the reactivity of TcHST-2, suggesting that the N-terminal ninth Trp might be a T cell epitope. This was confirmed by lack of antigenicity when using synthetic substituted peptides as well as minigenes coding F4.2 variant peptides with Ala or Arg at the ninth position of F4.2. Meanwhile, it was indicated that the sixth position Ile was critically important for the binding to HLA-A31 molecules. Thus, our data indicate that F4.2 may work as an HLA-A31-restricted natural antigenic peptide recognized by CTLs.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
A gene encoding human gastric signet ring cell carcinoma antigen recognized by HLA-A31-restricted cytotoxic T lymphocytes.
January 2002, Journal of immunotherapy (Hagerstown, Md. : 1997),
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.
February 1998, The Journal of experimental medicine,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
The mechanism of human autologous gastric signet ring cell tumor rejection by cytotoxic T lymphocytes in the possible context of HLA-A31 molecule.
March 1995, Cancer,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.
July 1999, Bone marrow transplantation,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes.
December 2003, Immunology letters,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes.
May 1991, Journal of immunological methods,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.
February 1995, The Journal of experimental medicine,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
December 2004, International journal of oncology,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes.
December 2003, International journal of molecular medicine,
K Suzuki, and H Sahara, and Y Okada, and T Yasoshima, and Y Hirohashi, and Y Nabeta, and I Hirai, and T Torigoe, and S Takahashi, and A Matsuura, and N Takahashi, and A Sasaki, and M Suzuki, and J Hamuro, and H Ikeda, and Y Wada, and K Hirata, and K Kikuchi, and N Sato
Antigenic structures recognized by cytotoxic T lymphocytes.
February 1991, The Journal of biological chemistry,
Copied contents to your clipboard!